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Following the results we previously reported on a series of ethyl 2-phenylthiomethyl 5-hydroxyindole-3-
carboxylate derivatives as 5-lipoxygenase (5-LOX) inhibitors, in order to obtain a more selective com-
pound with respect to the previous generation of derivatives, we decided to modify the structure of the
core ligand.
The ﬁrst level of structural modiﬁcation involved the annelation of benzene to the indole, yielding
corresponding benzo[g]indole derivatives, systematic optimization of methyl or chlorine groups in meta-
, ortho- and ortho/para-position of 2-phenylthiomethyl moiety were applied. The reported results show
that extension of the aromatic core led to a great enhancement of activity, especially in cell-free assay,
and the accurate structure-based design provided compounds 6f, 6g and 6l that block 5-LOX activity in
cell-free assays with IC50 ranging from 0.17 to 0.22 mM, and suppress 5-LOX product synthesis in poly-
morphonuclear leukocytes with IC50 ranging from 0.19 to 0.37 mM. Moreover we have identiﬁed 6f and 6l
as dual 5-lipoxygenase (5-LO) and microsomal prostaglandin E2 synthase-1 (mPGES-1) inhibitors and
compound 6l signiﬁcantly reduces inﬂammatory reactions in the carrageenan-induced mouse paw
oedema. The reported in vivo analysis, together with the accessible synthetic procedure, stimulate for the
generation of further potent antinﬂammatory benzoindoles-based agents.
© 2015 Published by Elsevier Masson SAS.1. Introduction
In the last decades, several studies have demonstrated the key
role played by 5-lipoxygenase (5-LOX) in inﬂammation-related
disorders. Leukotrienes (LT), formed from AA by catalysis of 5-
LOX, are fast reacting pro-inﬂammatory mediators of the immune
system [1,2]; besides their physiological roles, they primarily
mediate inﬂammatory and allergic reactions [3] and are involved in
the onset of inﬂammatory diseases such as asthma, allergic rhinitis,
rheumatoid arthritis and also cardiovascular disorder [4]. However,tal Medicine, Second Univer-
, Italy.
).
.numerous studies have demonstrated the overexpression of 5-LOX
in tissue samples of primary tumor cells as well as in established
cancer cell lines [5]. An increasing body of evidence suggests a
crucial role for 5-LOX products in the early stage of pancreatic,
prostate and colorectal carcinogenesis [6] and glioma cell lines [7].
Recent studies showed that 5-LOX expression appears to be upre-
gulated in patients with neurodegenerative disease like AD,
demonstrating the key role of leukotrienes promoting Ab genera-
tion [8e10]. In other reports, the potent and selective 5-LOX in-
hibitor zileuton reduced the amyloid and tau pathology as well as
memory impairments in different mouse models of AD [11,12].
Continuing our studies on small molecules able to block 5-LOX
activity [13e18], we recently reported the design and synthesis of
a small collection of differently decorated 5-hydroxyindole-3-
carboxylates derivatives able to interact with 5-LOX at nanomolar
SH
R
a
S
R
O
OEt
O
b
S
R
NH2
OEt
O
c
N
H
HO
O
OEt
S
R
4a-l
3a-l
5a-l
6a R: 3-Cl
6b R: 2-Cl
6c R: 2-CH3
6d R: 2,3-Cl
6e R: 3,4-Cl
6f R: 2,6-Cl
6g R: 3,5-Cl
6h R: 2,6-CH3
6i R: 3,5-CH3
6l R: 2,4,6-CH3
Scheme 1. Synthesis of compounds 6a-l. Reagents and conditions: a) 4-
chloroacetoacetate, NEt3, CH2Cl2, 0 C, 30 min; b) NH4OAc, HOAc toluene, reﬂux, 6h;
c) 1,4-naphtoquinone, ZnI2, CH2Cl2, reﬂux, 40 min.
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inﬂuence of the substitution pattern on the phenylthiomethyl
moiety, the simultaneous presence of chlorine in ortho-positions of
the thiophenol ring as well as the introduction of three methyl
groups (ortho, para) that led to compound with marked increase of
5-LOX inhibitory activity [14]. Among all tested compounds, ethyl
5-hydroxy-2-(mesitylthiomethyl)-1-methyl-1H-indole-3-
carboxylate (1) showed good potency in inhibiting 5-LOX activity in
cell-free assays with IC50 ¼ 0.7 mM and suppressed 5-LOX product
synthesis in polymorphonuclear leukocytes with IC50 ¼ 0.23 mM,
being equally potent to the well-recognized reference inhibitor
zileuton, used as antiasthmatic drug in the clinics. With regard to
other AA-metabolizing enzymes like COX-1, COX-2 and 12-LO,
compound 1was rather selective for 5-LOX with minor effects also
on 15-LOX. Moreover, our previous works reported that the anne-
lation of a [g]benzene ring to the indole led to more potent in-
hibitors, exempliﬁed by compounds 2a and 2b with IC50 of 0.086
and 0.097 mM in cell-free and 0.23 and 1.2 mM in cell-based assays,
respectively [19,20] (Fig. 1). We showed also that benzo[g]indol-3-
carboxylates potently inhibit mPGES-1 and thus represent a novel
class of dual 5-LO/mPGES-1 inhibitors.
With the goal of increasing potency and establishing a better
understanding of the pharmacophore for 5-LO inhibition, we
focused our investigation on the effects of introduction one or more
chlorine and methyl substituents on the benzoindole ring. More-
over, introduction of a methoxy or ethoxy group at C5 position and
N alkylation of the indole nitrogen atom (7a-b, 8a-b and 11) were
also carried out in order to investigate the effect of OH and NH on
the potency against 5-LOX.
Here we report the synthesis and the pharmacological proﬁle of
this second generation of benzoindole derivatives with anti-
inﬂammatory effectiveness in vivo. While further studies are
certainly needed to better describe the exact anti-inﬂammatory
mode of action, this novel focused small molecules library exerts
new interesting hits shedding further light on the structural re-
quirements needed for an optimal ligandeenzyme interaction.HO
O
OEt
RO
O
OEt2. Results and discussion
2.1. Chemistry
The synthesis of desired compounds 6a-l (Scheme 1) has been
accomplished in three steps of reaction. The ﬁnal Nenitzescu re-
action has proven to be the simplest entry into 5-hydroxy-1H-
benzo[g]indoles. Essentially, stirring of the enaminoesters 5a-lwith
1.0 equiv of 1,4-naphthoquinone in presence of catalytic amount of
ZnI2 at room temperature led to the expected 5-hydroxy-1H-benzo
[g]indoles. Nenitzescu reactants 5a-l were prepared starting from
thiophenols 3a-l, which were ﬁrst reacted with ethyl 4-
chloroacetoacetate to give the b-ketoesters 4a-l. b-Ketoesters 4a-l
were converted into their appropriate enaminoesters 5a-l by
reﬂuxing them in toluene with an excess of ammonium acetate. 7a-
b and 8a-b were prepared by alkylation of 6b with iodoalcanesHO
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Fig. 1. Chemical structure of compounds 1, 2a and 2b.under basic conditions using microwave irradiation. Protection of
the hydroxy group of 6b with tertbutyl dimethyl silyl chloride
(TBDSCl), alkylation with iodomethane and ﬁnal deprotection with
TBAF in THF allowed to obtain desired compound 11 in good yield
(Scheme 2) (see Scheme 3)
2.2. Evaluation of 5-LOX activity and structure-activity
Relationships
In order to assess the effects of the synthesized compounds on
5-LOX product synthesis, a cell-free assay using isolated human
recombinant 5-LOX and a cell-based assay using human neutro-
phils was applied. The cell-free assay allows identifying compounds
that directly interfere with 5-LOX catalytic activity, whereas the
cell-based test system considers cellular regulatory aspects of 5-
LOX product synthesis, and as such offers several points of attack
of a given compound (e.g., inhibition of FLAP or coactosine-like
protein (CLP), interference with 5-LOX-activating lipid hydroper-
oxides, protein kinases or Ca2þ mobilization, and 5-LOX trans-
location/membrane association) [21]. The reference 5-LOX
inhibitor N-[1-(1-benzothien-2-yl)ethyl]-N-hydroxyurea (zileuton)
was used to control the 5-LOX activity assays. As shown in Table 1,
all tested compounds (6a-l) which maintain OH and NH groups ina
N
H S
6b
Cl
N S
7a R= CH3, R1= H
7b R= CH3, R1= CH3
8a R= CH2CH3, R1= H
8b R= CH2CH3, R1= CH2CH3
Cl
R1
Scheme 2. Synthesis of compounds 7a-b and 8a-b. Reagents and conditions: a)
Iodomethane or iodoethane K2CO3, Acetone, MW, 30 min, 130 C.
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Scheme 3. Synthesis of compound 11. Reagents and conditions: a) Imidazole, TBDSCl,
CH2Cl2, 3h, rt; b) NaH, dry THF, 2h, 0 C; c) TBAF 1M in THF, THF, 10 min, 0 C.
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cell-based assaywith IC50 values in the lowmicromolar rangewhile
in cell-free test, the substituent plays a key role in the activity.
The corresponding 2-phenylthiomethyl benzoindoles of de-
rivatives 2a and 2b, 6a and 6b retain a good activity in cell-based
assay, especially for derivative 6b which is 6-fold more active
than 2b but they showed a decrease of potency in cell-free test. The
replacement of chlorine in position 2 with a methyl (6c vs 6b) does
not signiﬁcantly alter the efﬁciency in intact cells (IC50 ¼ 0.18 mM
and 0.26 mM respectively) while an improvement of activity is
observed in the cell-free assay (0.33 vs 0.82 mM). With regard to
polychlorinated derivatives, the position of the substituent is
fundamental for the activity, especially in the cell-free assay. In fact,
compounds 6f (2,6-Cl) and 6g (3,5-Cl) showed the best activity in
inhibiting 5-LOX, with IC50 values of 0.17 and 0.22 mM, respectively,
while the activity of compounds 6d (2,3 Cl) and 6e (3,4 Cl) is very
low, in particular for 6d with an IC50 > 1 mM. These results couldTable 1
Inhibition of 5-LOX activity of compounds 6a-l, 2a-b and zileuton in a cell-based assay (
5-LOX activity; cell-free
Cpd R n X IC50 (mM) Remai
6a 3-Cl 1 S >1 63.8 ±
6b 2-Cl 1 S 0.82 ± 0.03
6c 2-CH3 1 S 0.33 ± 0.15
6d 2,3-Cl 1 S >1 72 ±
6e 3,4-Cl 1 S 0.93 ± 0.03
6f 2,6-Cl 1 S 0.17 ± 0.11
6g 3,5-Cl 1 S 0.22 ± 0.07
6h 2,6-CH3 1 S >1 65.9 ±
6i 3,5-CH3 1 S >1 63 ±
6l 2,4,6-CH3 1 S 0.2 ± 0.06
2a 3-Cl 0 CH2 0.086 ± 0.0219
2b 2-Cl 0 CH2 0.097 ± 0.0919
Zileuton 0.614imply the presence of a bulky hydrophobic pocket in the binding
site of enzyme which allows the arrangement of two chlorines.
Considering IC50 values in cell-based assay, we observed a similar
activity for all polychlorinated derivatives especially for 6e, 6f and
6g, while 6d is slightly less active. This could be due a supple-
mentary mechanism of inhibition of 5-LOX product synthesis, by
interaction with other targets (i.e. FLAP or PLA2).
In the case of polymethylated molecules 6h, 6i and 6l, they
showed a comparable activity in cell-based conditions with IC50 of
0.17, 0.29 and 0.37 mM, respectively; otherwise only compound 6l
was active against isolated 5-LOX with an IC50 of 0.2 mM. The
alkylation of the hydroxy group of compound 6b led to compounds
7a and 8a which demonstrated a signiﬁcant decrease of activity,
especially in cell-based assays (IC50¼ 1.15 mM for 7a and 1.26 mM for
8b vs 0.182 mM for 6b). The di-alkylation of OH and NH groups is
detrimental for the activity, in fact, compounds 7b and 8b showed
an IC50 > 10 mM. The N-methyl derivative of 6b, i.e. compound 11, is
completely inactive with IC50 values > 10 mM in both assays
(Table 2). Unlike for indoles studied in our previous work [14], these
data demonstrate that in benzoindole derivatives the substitution
of hydrogen of the indole nitrogen with an alkyl residue is not
tolerated, maybe for a different positioning of molecule in the
active site.2.3. Anti-inﬂammatory effectiveness of derivatives 1, 6f, 6g, 6l in
carrageenan-induced paw oedema
In order to verify the anti-inﬂammatory efﬁcacy of the most
interesting compounds of the series, we evaluated their effect on
carrageenan-induced paw oedema, which represents a well-
established model of acute inﬂammation [22]. Many 5-LOX and
FLAP inhibitors that potently repressed 5-LOX product synthesis in
isolated cells failed to do so in carrageenan-induced acute inﬂam-
mation known as accompanied by elevated LT levels. Intraplantar
injection of carrageenan led to an increase in hind paw volume,
expressed as oedema, monitored for a period of 6 h. The increase in
paw volume (vehicle, i.p. treatment) reached a maximum at 4 h
post-carrageenan application (Fig. 2). Indole derivative 1 that pre-
viously showed potent inhibition of 5-LO in cell-basedintact PMNL) and in a cell-free assay. Data are given as mean ± S.E.M., n ¼ 3e4.
5-LOX activity; intact PMNL
ning activity at 1 mM (%) IC50 (mM) Remaining activity at 1 mM (%)
5 0.257 ± 0.1
0.182 ± 0.09
0.255 ± 0.05
14.8 0.657 ± 0.07
0.237 ± 0.09
0.19 ± 0.09
0.24 ± 0.12
5.7 0.17 ± 0.12
1.7 0.29 ± 0.07
0.37 ± 0.07
0.23 ± 0.0719
1.2 ± 0.0719
0.714
Table 2
Inhibition of 5-LOX activity of compounds 7a-b, 8a-b, 11 vs 6b in a cell-based assay (intact PMNL) and in a cell-free assay. Data are given as mean ± S.E.M., n ¼ 3e4.
5-LOX activity;
Cell-free
5-LOX activity;
Intact PMNL
Cpd R
0
R
00
IC50
(mM)
Remaining activity at 10 mM (%) IC50
(mM)
Remaining activity at 10 mM (%)
6b H H 0.82 ± 0.03 0.182 ± 0.09
7a CH3 H 1.74 ± 0.13 1.15 ± 0.12
7b CH3 CH3 >10 98.7 ± 2.3 >10 97.6 ± 1.5
8a CH2CH3 H 2.04 ± 0.139 1.26 ± 0.084
8b CH2CH3 CH2CH3 >10 99.4 ± 9.3 >10 95.5 ± 12.2
11 H CH3 >10 81.4 ± 13.2 >10 61.9 ± 12.3
Fig. 3. Effect of compounds 1 (4 mg/kg, i.p.), 6l (4 mg/kg, i.p.) and zileuton (20 mg/kg,
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lead structure [14]. We observed that 1 (1, 2 and 4 mg/kg, i.p.)
signiﬁcantly reduced paw oedema during the 2e4 h period in a
dose-dependent manner (Fig. 2). Futhermore, in agreement with
the results from intact cells, the corresponding benzoindole de-
rivative of 1, compound 6l was more efﬁcient in the in vivo test
(Fig. 3). Among the benzo[g]indol-3-carboxylates tested (see
Table 1), 6f and 6gwere the most efﬁcient to inhibit LTB4 formation
in cell-free assays and maintained their potency in intact PMNL.
In vivo experiment 6f failed to evoke signiﬁcant changes, while 6g
(1, 2 and 4 mg/kg, i.p.) decreased oedema, as compared with
vehicle-treated animals (Fig. 4). In fact, in mice treated with 4 mg/
kg 1, 6f, 6g or 6l, the peak of the response to carrageenan at 4 h was
reduced by 60.9%, 9.1%, 60%, and 77.4%, respectively, while zileuton
(20 mg/kg, i.p.), used as reference, caused only 38.2% inhibition.i.p.) on carrageenan-induced paw oedema 0e6 h after carrageenan injection. Data are
expressed as mean ± SEM (n ¼ 6e8 for each group). * or *** indicate signiﬁcant
(P < 0.05 or P < 0.001, respectively) differences vs carrageenan þ vehicle-treated
animals.2.4. Screening of indole-3-carboxylates 1, 6f, 6g, 6l as direct mPGES-
1inhibitors
Based on the potent anti-inﬂammatory efﬁcacy of 6l in vivo, the
compound may also interfere with other enzymes involved in the
generation of pro-inﬂammatory eicosanoids. Indeed, it may sup-
press other pro-inﬂammatory events such as the biosynthesis of
PGE2 as demonstrated for the related benzoindoles [20]. To conﬁrm
this hypothesis it was analyzed for inhibition of PGE2 formation inFig. 2. Effect of compounds 1 (1, 2, 4 mg/kg, i.p.) on carrageenan-induced paw oedema
0e6 h after carrageenan injection. Data are expressed as mean ± SEM (n ¼ 6e8 for
each group). * or *** indicate signiﬁcant (P < 0.05 or P < 0.001, respectively) differences
vs carrageenan þ vehicle-treated animals.
Fig. 4. Effect of compounds 6f (4 mg/kg, i.p.) and 6g (4 mg/kg, i.p.) on carrageenan-
induced paw oedema 0e6 h after carrageenan injection. Data are expressed as
mean ± SEM (n ¼ 6e8 for each group). * or *** indicate signiﬁcant (P < 0.05 or
P < 0.001, respectively) differences vs carrageenan þ vehicle-treated animals.the cell-free assay together with the test compounds(Table 3);
derivatives that achieved more than 50% inhibition at 10 mM, IC50
values were assessed.
Only a moderate inhibition of mPGES-1 activity was observed at
10 mM (27.8 ± 0.79%) for compound 1, enlargement of the hydro-
phobic core structure by annelation of benzene to the indole of 1,
yielding the corresponding benzo[g]indole derivate 6l, in accor-
dance with our previous results, led to an IC50 of 1.9 mM. Exchange
Table 3
Inhibition of m-PGES-1 activity of compounds l, 2a, 2b, 6f, 6g 6l. Data are given as mean ± S.E.M., n ¼ 3e4.
IC50 (mM)
mPGES-1
Cpd R n X IC50 (mM) Remaining
activity
a mM (%)
6f 2,6-Cl 1 S 1.33 ± 0.10
6g 3,5-Cl 1 S 13.84 ± 0.27
6l 2,4,6-CH3 1 S 1.93 ± 0.07
2a 3-Cl 0 CH2 57 ± 620
1 87.33 ± 3.88
A. Peduto et al. / European Journal of Medicinal Chemistry 108 (2016) 466e475470of the methyl by a chlorine substituents in o-position slightly
improved the potency (IC50 ¼ 1.33), while variation of the posi-
tioning of the chlorine in the thiol ring of 6g tometa (compound 6f)
was detrimental and led to an IC50 of 13.8 mM.
Although potent inhibition of mPGES-1 under cell-free condi-
tions must not necessarily result in efﬁcient suppression of in vivo
prostanoid formation the high potency on isolated mPGES-1well
correlate the peak of the response to carrageenan at 4 h in vivo of 6l.3. Conclusion
In this paper a series of new ethyl benzo[g]indole-3-carboxylate
was prepared and tested to evaluate their ability to inhibit 5-LOX
activity. Considering the in vitro biological data we suggest that
the ability to inhibit 5-LOX is closely related to the chemical
structures of the molecules.
Our studies allowed us to draw a tentative SAR proﬁle and to
optimize this series, in particular:
1. Alkylation of the indole nitrogen causes loss of activity (7b, 8b
and 11).
2. Substitution of hydroxyl group in position 5 of benzoindole ring
with methoxy or ethoxy residues decreases the potency (7a and
8a).
3. Substitutions on the thiophenol ring inﬂuences 5-LOX activity.
The simultaneous presence of chlorine in ortho or meta-
positions of the thiophenol ring (6f and 6g), as well as the
introduction of three methyl groups (6l) (ortho, para), causes a
marked increase of 5-LOX inhibitory activity in cell-free assays.
Moreover 6g and 6l are able to inhibit mPGES-1 activity in cell-
free and exhibit IC50 values of 1.33 mM and 1.93 mM respectively.
The antiﬂammatory properties of selected compounds (6f, 6g
and 6l) was conﬁrmed in vivo evaluating their ability to reduce
carrageenan-induced paw oedema. The most interesting com-
pound 6l caused a reduction of oedema of 77.4%, which is superior
over zileuton and indole 1 used as reference compounds.
Future studies addressing their anti-inﬂammatory effectiveness
in other animal models will reveal the therapeutic potential of
these new benzo[g]indole-3-carboxylates.4. Experimental section
4.1. Chemistry
All reagents were analytical grade and purchased from Sigma-
eAldrich (Milano, Italy). Flash chromatography was performed on
Carlo Erba silica gel 60 (230e400mesh; CarloErba, Milan, Italy). TLC
was carried out using plates coated with silica gel 60F 254 nm pur-
chased fromMerck (Darmstadt, Germany). 1H and 13C NMR spectra
were registered on a Brucker AC 300. Chemical shifts are reported in
ppm. The abbreviations used are follows: s, singlet; d, doublet; dd
double doublet; bs, broad signal. MS spectrometry analysis ESI-MS
was carried out on a Finnigan LCQ Deca ion trap instrument. Mi-
croanalyses were carried out on a Carlo Erba 1106 elemental
analyzer. Melting points were performed by Stuart melting point
SMP30 and are uncorrected. All microwave experiments were per-
formed in a self-tuning single mode Biotage Initiator Microwave.
4.2. General procedure for the synthesis of Ethyl 4-(thioaryloxy)
acetoacetates (4a-l)
A solution of 4-chloroacetoacetate (500 mg, 3.28 mmol, 1 eq.),
NEt3 (348mg, 3.44mmol,1.05 eq.) and appropriate thiophenols 3a-
l (1.03 eq.) in CH2Cl2 (6.5 mL) was stirred at 0 C for 30 min. The
reaction mixture was diluted with EtOAc and washed with an
aqueous solution of NaOH (1 M), hydrochloric acid (1 M) and brine.
The combined organic layers were dried (Na2SO4), ﬁltered and the
solvent was removed under reduced pressure. The residue was
puriﬁed by ﬂash chromatography (silica gel, hexane/EtOAc 9:1).
4.2.1. Ethyl 4-(3-chlorophenylthio)-3-oxobutanoate (4a)
Yield: 81%. 1H NMRdata are in agreement with those reported in
literature [23].
4.2.2. Ethyl 4-(2-chlorophenylthio)-3-oxobutanoate (4b)
Yield: 68%. 1H NMR data are in agreement with those reported
in literature [23].
4.2.3. Ethyl 4-(o-tolylthio)-3-oxobutanoate (4c)
Yield: 79%. 1H NMRdata are in agreement with those reported in
literature [24].
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Yield: 86%. 1H NMR (CDCl3, 300 MHz) d1.29 (t, 3H, J ¼ 7.34 Hz);
3.67 (s, 2H); 3.92 (s, 2H); 4.21 (q, 2H, J¼ 7.34 Hz); 7.19 (m, 2H); 7.34
(d, 1H, J ¼ 7.88 Hz).
4.2.5. Ethyl 4-(3,4-dichlorophenylthio)-3-oxobutanoate (4e)
Yield: 96%. 1H NMR data are in agreement with those reported in
literature [23].
4.2.6. Ethyl 4-(2,6-dichlorophenylthio)-3-oxobutanoate (4f)
Yield: 88%. 1H NMR data are in agreement with those reported in
literature [23].
4.2.7. Ethyl 4-(3,5-dichlorophenylthio)-3-oxobutanoate (4g)
Yield: 62%. 1H NMR data are in agreement with those reported in
literature [23].
4.2.8. Ethyl 4-(2,6-dimethylphenylthio)-3-oxobutanoate (4h)
Yield: 85%.1H NMR (CDCl3, 300 MHz) d 1.29 (t, 3H, J ¼ 7.34 Hz);
2.59 (s, 6H),; 3.53 (s, 2H); 3.55 (s, 2H); 4.18 (q, 2H, J ¼ 7.34 Hz);
7.09e7.19 (m, 3H).
4.2.9. Ethyl 4-(3,5-dimethylphenylthio)-3-oxobutanoate (4i)
Yield: 92%. 1H NMR (CDCl3, 300 MHz) d 1.28 (t, 3H, J ¼ 7.34 Hz);
2.29 (s, 6H); 3.65 (s, 2H); 3.80 (s, 2H); 4.20 (q, 2H, J ¼ 7.34 Hz); 6.88
(s 1H); 6.98 (s, 2H).
4.2.10. Ethyl 4-(mesitylthio)-3-oxobutanoate (4l)
Yield: 86%. 1H NMR (CDCl3, 300 MHz) d 1.37 (t, 3H, J ¼ 7.34 Hz);
2.20 (s, 3H); 2.45 (s, 6H); 3.58 (s, 2H); 3.60 (s, 2H); 4.17 (q, 2H,
J ¼ 7.34 Hz); 6.87 (s, 2H).
4.3. General procedure for the synthesis of Ethyl 4-(thioaryloxy)
enaminoesters (5a-l)
The appropriate b-ketoester 4a-l (3.0 mmol) and ammonium
acetate (1.16 g, 15.0 mmol) were dissolved in dry toluene (10 mL).
After adding four drops of acetic acid, the reaction mixture was
reﬂuxed for 6 h under azeotropic removal of water. After cooling
down to RT, the mixture was washed with saturated aqueous
NaHCO3 solution. The resulting organic layer was dried over
Na2SO4, ﬁltered, and evaporated to give a residue, which was pu-
riﬁed by ﬂash chromatography on silica gel (hexane/Ethyl acetate
9:1).
4.3.1. (Z)-ethyl 4-(3-chlorophenylthio)-3-aminobut-2-enoate (5a)
Yield: 45%. 1H NMR (CDCl3, 300 MHz) d 1.28 (t, 3H, J ¼ 7.34 Hz);
3.63 (s, 2H); 4.14 (q, 2H, J¼ 7.34 Hz); 4.67 (s,1H); 7.20e7.25 (m, 3H);
7.34 (s, 1H).
4.3.2. (Z)-ethyl 4-(2-chlorophenylthio)-3-aminobut-2-enoate (5b)
Yield: 67%. 1H NMR (CDCl3, 300 MHz) d 1.27 (t, 3H, J ¼ 7.34 Hz);
3.69 (s, 2H); 4.15 (q, 2H, J¼ 7.34 Hz); 4.70 (s,1H); 7.18 (td,1H, J¼ 1.5,
7.2 Hz); 7.24 (td,1H, J¼ 1.5, 7.2 Hz); 7.33 (dd,1H, J¼ 1.5, 7.2 Hz); 7.40
(dd, 1H, J ¼ 1.5, 7.2 Hz).
4.3.3. (Z)-ethyl 4-(o-tolylthio)-3-aminobut-2-enoate (5c)
Yield: 87%. 1H NMR (CDCl3, 300 MHz) d 1.23 (t, 3H, J ¼ 7.34 Hz);
2.38 (s, 3H); 3.67 (s, 2H); 4.12 (q, 2H, J ¼ 7.34 Hz); 4.67 (s, 1H);
7.08e7.22 (m, 4H).
4.3.4. (Z)-ethyl 4-(2,3-dichlorophenylthio)-3-aminobut-2-enoate
(5d)
Yield:73%. 1H NMR (CDCl3, 300 MHz) d 1.28 (t, 3H, J ¼ 7.34 Hz);
3.70 (s, 2H); 4.13 (q, 2H, J¼ 7.34 Hz); 4.73 (s, 1H); 7.15e7.22 (m, 2H);7.34 (dd, 1H, J ¼ 2.4, 6.9 Hz).4.3.5. (Z)-ethyl 4-(3,4-dichlorophenylthio)-3-aminobut-2-enoate
(5e)
Yield: 62%. 1H NMR (CDCl3, 300 MHz) d 1.27 (t, 3H, J ¼ 7.34 Hz);
3.59 (s, 2H); 4.14 (q, 2H, J¼ 7.34 Hz); 4.64 (s,1H); 7.18 (dd,1H J¼ 2.1,
8.4 Hz); 7.38 (d, 1H, J ¼ 8.4 Hz); 7.45 (s, 1H).4.3.6. (Z)-ethyl 4-(2,6-dichlorophenylthio)-3-aminobut-2-enoate
(5f)
Yield: 73%. 1H NMR (CDCl3, 300 MHz) d 1.22 (t, 3H, J ¼ 7.34 Hz);
3.63 (s, 2H); 4.08 (q, 2H, J ¼ 7.34 Hz); 4.50 (s, 1H); 7.37 (t, 1H,
J ¼ 7.88 Hz); 7.48 (d, 2H, J ¼ 7.88 Hz).4.3.7. (Z)-ethyl 4-(3,5-dichlorophenylthio)-3-aminobut-2-enoate
(5g)
Yield: 59%. 1H NMR (CDCl3, 300 MHz) d 1.24 (t, 3H, J ¼ 7.34 Hz);
3.62 (s, 2H); 4.13 (q, 2H, J ¼ 7.34 Hz); 4.70 (s, 1H); 7.21 (d, 3H,
J ¼ 1.9 Hz).4.3.8. (Z)-ethyl 4-(2,6-dimethylphenylthio)-3-aminobut-2-enoate
(5h)
Yield: 68%. 1H NMR (CDCl3, 300 MHz) d 1.28 (t, 3H, J ¼ 7.34 Hz);
2.55 (s, 6H); 3.28 (s, 2H); 4.14 (q, 2H, J ¼ 7.34 Hz); 4.43 (s, 1H);
7.09e7.19 (m, 3H).4.3.9. (Z)-ethyl 4-(3,5-dimethylphenylthio)-3-aminobut-2-enoate
(5i)
Yield: 53%. 1H NMR (CDCl3, 300 MHz) d 1.27 (t, 3H, J ¼ 7.34 Hz);
2.29 (s, 6H); 3.60 (s, 2H); 4.16 (q, 2H, J ¼ 7.34 Hz); 4.65 (s, 1H); 6.87
(s, 1H); 6.98 (s, 2H).4.3.10. (Z)-ethyl 3-amino-4-(mesitylthio)but-2-enoate (5l)
Yield: 58%. 1H NMR (CD3OD-d4, 300 MHz) d 1.20 (t, 3H,
J ¼ 7.34 Hz); 2.28 (s, 3H); 2.52 (s, 6H); 3.22 (s, 2H); 4.05 (q, 2H,
J ¼ 7.34 Hz); 4.13 (s, 1H); 4.65 (br, NH2); 6.98 (s, 2H).4.4. General procedure for the synthesis of 5-Hydroxy-1H-benzo[g]
indole-3-carboxylate (6a-l)
To a solution of 1,4-naphthoquinone (1.0 mmol) in 3 mL CH2Cl2,
ZnI2 (32.0 mg, 0.1 mmol) was added and the resulting mixture was
heated to boiling temperature. A solution of enaminoesters 5a-l,
respectively (1.0 mmol), in 2 mL of CH2Cl2 was added drop by drop
under stirring for 5e10 min. After reﬂuxing for additional 20 min,
the mixture was cooled to 0e5 C for 2e3 h. The precipitated
crystals were ﬁltered off and washed with CH2Cl2 and hexane.4.4.1. Ethyl 2-((3-chlorophenylthio)methyl)-5-hydroxy-1H-benzo
[g]indole-3-carboxylate (6a)
Rf (hexane/ethyl acetate 8:2)¼ 0.28. Yield: 4%. M.p. 167.5 C dec.
1H NMR (DMSO-d6, 300 MHz) d 1.35 (t, 3H, J¼ 7.34 Hz); 4.28 (q, 2H,
J ¼ 7.34 Hz); 4.77 (s, 2H); 7.25e732 (m, 3H); 7.40e747 (m, 2H); 7.51
(s, 1H); 7.55 (t, 1H, J ¼ 6.61 Hz); 8.16 (d, 1H, J ¼ 7.80 Hz); 8.27 (d, 1H,
J ¼ 7.80 Hz); 9.69 (s, 1H, OH); 12.39 (s, 1H, NH). 13C NMR (DMSO-d6,
75 MHz) d 14.4, (CH3CH2), 29.3 (CH2S), 59.9, (CH3CH2), 100.1 (C-3),
121.4 (C-5a),121.7 (C-9),121.8 (C-4),122.7 (C-3a),125.1 (C-9b),126.5
(C-9a), 126.8e127.6 (C-6, C-7, C-8, C-20, C-40, C-50, C-60), 131.5 (C-10),
133.4 (C-5), 134.5 (C-30), 143.8 (C-2), 165.5 (C]O). MS-ESI (m/z):
410.06 [M]. Anal. Calcd. for C22H18ClNO3S C, 64.15; H, 4.40; Cl,
8.61; N, 3.40; O, 11.65; S, 7.78. Found C, 63.10; H, 4.45; Cl, 8.53; N,
3.32; O, 11.54; S, 7.62.
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[g]indole-3-carboxylate (6b)
Rf (hexane/ethyl acetate 8:2) ¼ 0.24. Yield: 21%. M.p. 209.0 C
dec. 1H NMR (DMSO-d6, 300MHz) d 1.33 (t, 3H, J¼ 7.34 Hz); 4.26 (q,
2H, J ¼ 7.34 Hz); 4.71 (s, 2H); 7.22 (t, 1H, J ¼ 6.30 Hz); 7.35 (t, 1H,
J¼ 6.30 Hz); 7.42 (d,1H, J¼ 8.10 Hz); 7.49 (d,1H, J¼ 8.10 Hz); 7.53 (s,
1H); 7.55e7.60 (m, 2H); 8.16 (d, 1H, J ¼ 7.80 Hz); 8.27 (d, 1H,
J ¼ 7.80 Hz); 9.69 (s, 1H, OH); 12.39 (s, 1H, NH). 13C NMR (DMSO-d6,
75 MHz) d 14.4, (CH3CH2), 29.3 (CH2S), 59.9, (CH3CH2), 100.1 (C-3),
121.4 (C-5a),121.7 (C-9),121.8 (C-4),122.7 (C-3a),125.1 (C-9b),126.5
(C-9a), 126.8e127.6 (C-6, C-7, C-8, C-30, C-40, C-50, C-60), 131.5 (C-10),
132.3 (C-20), 133.4 (C-5), 143.8 (C-2), 165.5 (C]O). MS-ESI (m/z):
410.01 [M]. Anal. Calcd. for C22H18ClNO3S C, 64.15; H, 4.40; Cl,
8.61; N, 3.40; O, 11.65; S, 7.78 Found C, 63.75; H, 3.84; Cl, 8.15; N,
3.07; O, 11.25; S, 7.48.
4.4.3. Ethyl 2-((o-tolylthio)methyl)-5-hydroxy-1H-benzo[g]indole-
3-carboxylate (6c)
Rf (hexane/ethyl acetate 8:2) ¼ 0.24. Yield: 56%. M.p. 184.5 C
dec. 1H NMR (DMSO-d6, 300 MHz) d 1.37 (t, 3H, J¼ 7.34 Hz); 2.22 (s,
3H); 4.26 (q, 2H, J ¼ 7.34 Hz); 4.70 (s, 2H); 6.83e6.94 (m, 4H); 7.42
(t, 1H, J ¼ 7.88 Hz); 7.52 (s, 1H); 7.57 (t, 1H, J ¼ 7.88 Hz); 8.15 (d, 1H,
J ¼ 7.88 Hz); 8.30 (d, 1H, J ¼ 7.88 Hz); 9.69 (s, 1H, OH); 12.39 (s, 1H,
NH). 13C NMR (DMSO-d6, 75 MHz) d 14.4, (CH3CH2), 19.2, (o-CH3),
29.3 (CH2S), 59.9, (CH3CH2), 100.1 (C-3), 121.4 (C-5a), 121.7 (C-9),
121.8 (C-4), 122.7 (C-3a), 125.1 (C-9b), 126.5 (C-9a), 126.8e127.6 (C-
6, C-7, C-8, C-20, C-30, C-40, C-50, C-60), 131.5 (C-10), 133.4 (C-5), 143.8
(C-2), 165.5 (C]O). MS-ESI (m/z): 390.13 [M]. Anal. Calcd. for
C23H21NO3S C, 70.56; H, 5.41; N, 3.58; O, 12.26; S, 8.19 Found C,
71.48; H, 6.31; N, 4.23; O, 11.59; S, 7.37.
4.4.4. Ethyl 2-((2,3-dichlorophenylthio)methyl)-5-hydroxy-1H-
benzo[g]indole-3-carboxylate (6d)
Rf (hexane/ethyl acetate 8:2) ¼ 0.22. Yield: 29%. M.p. 184.1 C
dec. 1H NMR (DMSO-d6, 300MHz) d 1.33 (t, 3H, J¼ 7.34 Hz); 4.26 (q,
2H, J ¼ 7.34 Hz); 4.71 (s, 2H); 7.38 (t, 1H, J ¼ 6.30 Hz); 7.47 (t, 1H,
J¼ 6.30 Hz); 7.53 (s,1H); 7.55e7.60 (m, 3H); 8.16 (d,1H, J¼ 7.80 Hz);
8.27 (d, 1H, J¼ 7.80 Hz); 9.69 (s, 1H, OH); 12.39 (s, 1H, NH). 13C NMR
(DMSO-d6, 75 MHz) d 14.4, (CH3CH2), 29.3 (CH2S), 59.9, (CH3CH2),
100.1 (C-3), 121.4 (C-5a), 121.7 (C-9), 121.8 (C-4), 122.7 (C-3a), 125.1
(C-9b), 126.5 (C-9a), 126.8e127.6 (C-6, C-7, C-8, C-40, C-50, C-60),
137.5 (C-10), 132.3 (C-20-C-30), 133.4 (C-5), 143.8 (C-2), 165.5 (C]O).
MS-ESI (m/z): 446.05 [M]. Anal. Calcd. for C22H17Cl2NO3S C, 59.20;
H, 3.84; Cl, 15.89; N, 3.14; O,10.75; S, 7.18 Found C, 58.73; H, 3.24; Cl,
15.19; N, 2.86; O, 10.05; S, 7.03.
4.4.5. Ethyl 2-((3,4-dichlorophenylthio)methyl)-5-hydroxy-1H-
benzo[g]indole-3-carboxylate (6e)
Rf (hexane/ethyl acetate 8:2) ¼ 0.26. Yield: 16%. M.p. 183.5 C
dec. 1H NMR (DMSO-d6, 300MHz) d 1.35 (t, 3H, J¼ 7.34 Hz); 4.28 (q,
2H, J ¼ 7.34 Hz); 4.77 (s, 2H); 7.32 (d, 1H J ¼ 6.63 Hz); 7.43 (t, 1H,
J¼ 6.61 Hz); 7.48e7.52 (m, 3H); 7.64 (s,1H); 8.16 (d,1H, J¼ 7.80 Hz);
8.27 (d, 1H, J¼ 7.80 Hz); 9.69 (s, 1H, OH); 12.39 (s, 1H, NH). 13C NMR
(DMSO-d6, 75 MHz) d 14.4, (CH3CH2), 29.3 (CH2S), 59.9, (CH3CH2),
100.1 (C-3), 121.4 (C-5a), 121.7 (C-9), 121.8 (C-4), 122.7 (C-3a), 125.1
(C-9b), 126.5 (C-9a), 126.8e127.6 (C-6, C-7, C-8, C-20, C-50, C-60),
129.8 (C-40), 131.5 (C-10), 133.4 (C-5), 133.6 (C-30), 143.8 (C-2), 165.5
(C]O). MS-ESI (m/z): 445.94 [M]. Anal. Calcd. for C22H17Cl2NO3S
C, 59.20; H, 3.84; Cl, 15.89; N, 3.14; O, 10.75; S, 7.18 Found C, 58.70;
H, 3.54; Cl, 15.37; N, 3.02; O, 10.25; S, 7.07.
4.4.6. Ethyl 2-((2,6-dichlorophenylthio)methyl)-5-hydroxy-1H-
benzo[g]indole-3-carboxylate (6f)
Rf (hexane/ethyl acetate 8:2) ¼ 0.18. Yield: 35%. M.p. 191.8 C
dec. 1H NMR (Acetone-d6, 300 MHz) d 1.33 (t, 3H, J ¼ 7.34 Hz); 4.17(q, 2H, J¼ 7.34 Hz); 4.70 (s, 2H); 7.32e7.55 (m, 4H); 7.64 (s,1H); 8.16
(d, 1H, J ¼ 7.88 Hz); 8.29 (d, 1H, J ¼ 7.88 Hz); 8.64 (s, 1H, OH). 13C
NMR (DMSO-d6, 75 MHz) d 14.4, (CH3CH2), 29.3 (CH2S), 59.9,
(CH3CH2), 100.1 (C-3), 121.4 (C-5a), 121.7 (C-9), 121.8 (C-4), 122.7 (C-
3a), 125.1 (C-9b), 126.5 (C-9a), 126.8e127.6 (C-6, C-7, C-8, C-30, C-40,
C-50), 130.3 (C-20-C-60), 131.5 (C-10), 133.4 (C-5), 143.8 (C-2), 165.5
(C]O). MS-ESI (m/z): 444.02 [M]. Anal. Calcd. for C22H17Cl2NO3S C,
59.20; H, 3.84; Cl, 15.89; N, 3.14; O, 10.75; S, 7.18 Found C, 60.27; H,
3.59; Cl, 16.07; N, 3.82; O, 11.25; S, 7.87.
4.4.7. Ethyl 2-((3,5-dichlorophenylthio)methyl)-5-hydroxy-1H-
benzo[g]indole-3-carboxylate (6g)
Rf (hexane/ethyl acetate 8:2) ¼ 0.26. Yield: 17%. M.p. 203.0 C
dec. 1H NMR (DMSO-d6, 300MHz) d 1.37 (t, 3H, J¼ 7.34 Hz); 4.30 (q,
2H, J ¼ 7.34 Hz); 4.82 (s, 2H); 7.41e7.47 (m, 3H); 7.52 (s, 1H); 7.57 (t,
1H, J ¼ 7.88 Hz); 8.17 (d, 1H, J ¼ 7.88 Hz); 8.28 (d, 1H, J ¼ 7.88 Hz);
9.69 (s, 1H, OH); 12.39 (s, 1H, NH). 13C NMR (DMSO-d6, 75 MHz)
d 14.4, (CH3CH2), 29.3 (CH2S), 59.9, (CH3CH2), 100.1 (C-3), 121.4 (C-
5a), 121.7 (C-9), 121.8 (C-4), 122.7 (C-3a), 125.1 (C-9b), 126.5 (C-9a),
126.8e127.6 (C-6, C-7, C-8, C-20, C-40, C-60), 131.5 (C-10), 133.4 (C-5),
135.6 (C-30-C-50), 143.8 (C-2), 165.5 (C]O). MS-ESI (m/z): 445.92
[M]. Anal. Calcd. for C22H17Cl2NO3S C, 59.20; H, 3.84; Cl, 15.89; N,
3.14; O, 10.75; S, 7.18 Found C, 60.21; H, 4.03; Cl, 14.84; N, 2.89; O,
10.60; S, 7.23.
4.4.8. Ethyl 2-((2,6-dimethylphenylthio)methyl)-5-hydroxy-1H-
benzo[g]indole-3-carboxylate (6h)
Rf (hexane/ethyl acetate 8:2) ¼ 0.30. Yield: 37%. M.p. 197.5 C
dec.1H NMR (DMSO-d6, 300 MHz) d 1.26 (t, 3H, J ¼ 7.34 Hz); 2.29 (s,
6H); 4.08 (q, 2H, J¼ 7.34 Hz); 4.40 (s, 2H); 7.02e7.18 (m, 3H); 7.42 (t,
1H, J ¼ 6.61 Hz); 7.47 (s, 1H); 7.54 (t, 1H, J ¼ 6.61 Hz); 8.16 (d, 1H,
J ¼ 7.80 Hz); 8.27 (d, 1H, J ¼ 7.80 Hz); 9.64 (s, 1H, OH); 12.39 (s, 1H,
NH). 13C NMR (DMSO-d6, 75 MHz) d 14.4, (CH3CH2), 19.2, (o,m-CH3),
29.3 (CH2S), 59.9, (CH3CH2), 100.1 (C-3), 121.4 (C-5a), 121.7 (C-9),
121.8 (C-4), 122.7 (C-3a), 125.1 (C-9b), 126.5 (C-9a), 126.8e127.6 (C-
6, C-7, C-8, C-20, C-30, C-40, C-50, C-60), 131.5 (C-10), 133.4 (C-5), 143.8
(C-2), 165.5 (C]O). MS-ESI (m/z): 404.14 [M]. Anal. Calcd. for
C24H23NO3S C, 71.09; H, 5.72; N, 3.45; O, 11.84; S, 7.91 Found C,
70.89; H, 5.22; N, 3.05; O, 10.82; S, 7.37.
4.4.9. Ethyl 2-((3,5-dimethylphenylthio)methyl)-5-hydroxy-1H-
benzo[g]indole-3-carboxylate (6i)
Rf (hexane/ethyl acetate 8:2) ¼ 0.28. Yield: 37%. M.p. 158.3 C
dec. 1H NMR (DMSO-d6, 300 MHz) d 1.35 (t, 3H, J¼ 7.34 Hz); 2.20 (s,
6H); 4.26 (q, 2H, J ¼ 7.34 Hz); 4.71 (s, 2H); 6.83 (s, 1H); 6.98 (s, 2H);
7.42 (t, 1H, J ¼ 7.88 Hz); 7.52 (s, 1H); 7.57 (t, 1H, J ¼ 7.88 Hz); 8.17 (d,
1H, J ¼ 7.88 Hz); 8.31 (d, 1H, J ¼ 7.88 Hz); 9.69 (s, 1H, OH); 12.39 (s,
1H, NH). 13C NMR (DMSO-d6, 75 MHz) d14.4, (CH3CH2), 24.2 (m-
CH3), 29.3 (CH2S), 59.9, (CH3CH2), 100.1 (C-3), 121.4 (C-5a), 121.7 (C-
9), 121.8 (C-4), 122.7 (C-3a), 125.1 (C-9b), 126.5 (C-9a), 126.8e127.6
(C-6, C-7, C-8, C-20, C-40, C-60), 131.5 (C-10), 133.4 (C-5), 138.5 (C-30,C-
50), 143.8 (C-2), 165.5 (C]O). MS-ESI (m/z): 404.10 [M]. Anal.
Calcd. for C24H23NO3S C, 71.09; H, 5.72; N, 3.45; O, 11.84; S, 7.91
Found C, 70.89; H, 6.92; N, 2.98; O, 11.24; S, 7.37.
4.4.10. Ethyl 5-hydroxy-2-((mesitylthio)methyl)-1H-benzo[g]
indole-3-carboxylate (6l)
Rf (hexane/ethyl acetate 8:2) ¼ 0.28. Yield: 27%. M.p. 178.5 C
dec. 1H NMR (Acetone-d6, 300 MHz) d 1.32 (t, 3H, J ¼ 7.34 Hz); 2.20
(s, 3H); 2.25 (s, 6H); 4.17 (q, 2H, J ¼ 7.34 Hz); 4.44 (s, 2H); 6.87 (s,
2H); 7.45 (t, 1H, J ¼ 7.88 Hz); 7.53 (t, 1H, J ¼ 7.88 Hz); 7.65 (s, 1H);
8.15 (d,1H, J¼ 7.88 Hz); 8.29 (d,1H, J¼ 7.88 Hz); 8.67 (s,1H, OH). 13C
NMR (DMSO-d6, 75 MHz) d 14.4, (CH3CH2), 19.2, (o,m-CH3), 24.9 (p-
CH3), 29.3 (CH2S), 59.9, (CH3CH2), 100.1 (C-3), 121.4 (C-5a), 121.7 (C-
9), 121.8 (C-4), 122.7 (C-3a), 125.1 (C-9b), 126.5 (C-9a), 126.8e127.6
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143.8 (C-2),165.5 (C]O). MS-ESI (m/z): 418.09 [M]. Anal. Calcd. for
C25H25NO3S C, 71.57; H, 6.01; N, 3.34; O, 11.44; S, 7.64. Found C,
70.59; H, 6.12; N, 3.25; O, 11.37; S, 7.56.4.5. General procedure for the synthesis of 7a-b and 8a-b
A mixture of 6b (34 mg, 0.08 mmol), K2CO3 (57 mg, 0.40 mmol),
and iodoalcane (3.75 eq.) in acetone (0.3 mL) was irradiated under
MW, for 30 min at 130 C. The mixture was ﬁltered and evaporated
under vacuum. The crude was puriﬁed by ﬂash chromatography on
silica gel (hexane/Ethyl acetate 9:1).4.5.1. Ethyl 2-((2-chlorophenylthio)methyl)-5-methoxy-1H-benzo
[g]indole-3-carboxylate (7a)
Rf (hexane/ethyl acetate 8:2)¼ 0.5. Yield: 27%. M.p.188.5 C dec.
1H NMR (CDCl3, 300 MHz) d 1.50 (t, 3H, J ¼ 7.34 Hz); 4.15 (s, 3H);
4.26 (q, 2H, J¼ 7.34 Hz); 4.81 (s, 2H); 7.22 (t, 1H, J¼ 6.30 Hz); 7.35 (t,
1H, J ¼ 6.30 Hz); 7.42 (d, 1H, J ¼ 8.10 Hz); 7.49 (d, 1H, J ¼ 8.10 Hz);
7.53 (s, 1H); 7.55e7.60 (m, 2H); 8.16 (d, 1H, J ¼ 7.80 Hz); 8.27 (d, 1H,
J¼ 7.80 Hz). Anal. Calcd. for C23H20ClNO3S C, 64.86; H, 4.73; Cl, 8.32;
N, 3.29; O, 11.27; S, 7.53. Found C, 64.88; H, 4.76; Cl, 8.35; N, 3.32; O,
11.30; S, 7.50.4.5.2. Ethyl 2-((2-chlorophenylthio)methyl)-5-methoxy-1-methyl-
1H-benzo[g]indole-3-carboxylate (7b)
Rf (hexane/ethyl acetate 8:2) ¼ 0.72. Yield: 32%. M.p. 198.5 C
dec. 1H NMR (CDCl3, 300 MHz) d 1.50 (t, 3H, J ¼ 7.34 Hz); 4.10 (s,
3H); 4.15 (s, 3H); 4.26 (q, 2H, J ¼ 7.34 Hz); 4.80 (s, 2H); 7.22 (t, 1H,
J ¼ 6.30 Hz); 7.35 (t, 1H, J ¼ 6.30 Hz); 7.42 (d, 1H, J ¼ 8.10 Hz); 7.49
(d, 1H, J ¼ 8.10 Hz); 7.53 (s, 1H); 7.55e7.60 (m, 2H); 8.16 (d, 1H,
J ¼ 7.80 Hz); 8.27 (d, 1H, J ¼ 7.80 Hz). Anal. Calcd. for C24H22ClNO3S
C, 65.52; H, 5.04; Cl, 8.06; N, 3.18; O, 10.91; S, 7.29. Found C, 65.50;
H, 5.08; Cl, 8.09; N, 3.21; O, 10.89; S, 7.32.4.5.3. Ethyl 2-((2-chlorophenylthio)methyl)-5-ethoxy-1H-benzo[g]
indole-3-carboxylate (8a)
Rf (hexane/ethyl acetate 8:2)¼ 0.5. Yield: 25%. M.p.179.3 C dec.
1H NMR (CDCl3, 300 MHz) d 1.53 (t, 3H, J ¼ 7.34 Hz); 1.63 (t, 3H,
J ¼ 7.5 Hz); 4.26 (q, 2H, J ¼ 7.34 Hz); 4.50 (q, 2H, J ¼ 7.5 Hz); 4.80 (s,
2H); 7.22 (t, 1H, J ¼ 6.30 Hz); 7.35 (t, 1H, J ¼ 6.30 Hz); 7.42 (d, 1H,
J¼ 8.10 Hz); 7.49 (d,1H, J¼ 8.10 Hz); 7.53 (s, 1H), 7.55e7.60 (m, 2H);
8.16 (d, 1H, J ¼ 7.80 Hz); 8.27 (d, 1H, J ¼ 7.80 Hz). 13C NMR (CDCl3,
75 MHz) d 14.4, (CH3CH2), 19.2 (CH3CH2), 30.0 (CH2S), 59.9
(CH3CH2), 63.9 (CH3CH2), 99.0 (C-3), 121.4 (C-5a), 121.7 (C-9), 121.8
(C-4), 122.7 (C-3a), 125.1 (C-9b), 126.5 (C-9a), 126.8e127.6 (C-6, C-7,
C-8, C-20, C-30, C-40, C-50, C-60), 131.5 (C-10), 133.4 (C-5), 143.8 (C-2),
165.5 (C]O). Anal. Calcd. for C24H22ClNO3S C, 65.52; H, 5.04; Cl,
8.06; N, 3.18; O, 10.91; S, 7.29. Found C, 65.44; H, 5.09; Cl, 8.09; N,
3.20; O, 10.88; S, 7.32.4.5.4. Ethyl 2-((2-chlorophenylthio)methyl)-5-ethoxy-1-ethyl-1H-
benzo[g]indole-3-carboxylate (8b)
Rf (hexane/ethyl acetate 8:2) ¼ 0.68. Yield: 33%. M.p. 158.5 C
dec. 1H NMR (CDCl3, 300 MHz) d 1.53 (t, 3H, J ¼ 7.34 Hz); 1.61 (m,
6H); 4.26 (q, 2H, J ¼ 7.34 Hz); 4.50 (m, 4H); 4.80 (s, 2H); 7.22 (t, 1H,
J ¼ 6.30 Hz); 7.35 (t, 1H, J ¼ 6.30 Hz); 7.42 (d, 1H, J ¼ 8.10 Hz); 7.49
(d, 1H, J ¼ 8.10 Hz); 7.53 (s, 1H); 7.55e7.60 (m, 2H); 8.16 (d, 1H,
J ¼ 7.80 Hz); 8.27 (d, 1H, J ¼ 7.80 Hz). Anal. Calcd. for C26H26ClNO3S
C, 66.73; H, 5.60; Cl, 7.58; N, 2.99; O, 10.26; S, 6.85. Found C, 66.77;
H, 5.66; Cl, 7.55; N, 3.02; O, 10.23; S, 6.89.4.6. Ethyl 2-((2-chlorophenylthio)methyl)-5-hydroxy-1-methyl-
1H-benzo[g]indole-3-carboxylate (11)
A solution of 6b (152 mg, 0.37 mmol), imidazole (93 mg,
1.48 mmol) and tert-butyl dimethyl silyl chloride (127 mL,
0.74 mmol) in CH2Cl2 was stirred for 3 h at room temperature. The
mixture was washed with water and two times with brine. The
organic layer, dried over anhydrous Na2SO4, was evaporated under
reduced pressure and the crude was puriﬁed by ﬂash chromatog-
raphy (eluting system hexane/ethyl acetate 8:2) affording 185 mg
of desired compound (9) as white cristals (yield: 95%). 1H NMR
(CDCl3, 300MHz) d 0.18 (s, 6H); 1.01 (s, 9H); 1.34 (t, 3H, J¼ 7.34 Hz);
4.28 (q, 2H, J¼ 7.34 Hz); 4.70 (s, 2H); 7.22 (t, 1H, J¼ 6.30 Hz); 7.35 (t,
1H, J ¼ 6.30 Hz); 7.42 (d, 1H, J ¼ 8.10 Hz); 7.49 (d, 1H, J ¼ 8.10 Hz);
7.53 (s, 1H); 7.55e7.60 (m, 2H); 8.16 (d, 1H, J ¼ 7.80 Hz); 8.27 (d, 1H,
J ¼ 7.80 Hz).
A 25 mL three-necked round bottomed ﬂask equipped with a
stir bar was charged with 60% NaH (21 mg, 0.53 mmol) in mineral
oil dissolved in 1 mL of dry THF, under nitrogen atmosphere. The
solutionwas cooled at 0 C and a solution of 9 (185 mg, 0.35 mmol)
in 2 mL of dry THF was added. After 30 min iodomethane (26 mL,
0.42 mmol) was added and the mixture was stirred for 2 h. The
mixture was diluted with water and extracted with CH2Cl2. Organic
layer was washed with brine, dried over anhydrous Na2SO4 and
evaporated under reduced pressure. Desired compound (10) was
obtained after puriﬁcation with ﬂash chromatography using hex-
ane/ethyl acetate 9:1, as eluent mixture. (Yield: 50%). 1H NMR
(CDCl3, 300MHz) d 0.18 (s, 6H); 1.01 (s, 9H); 1.33 (t, 3H, J¼ 7.34 Hz);
4.10 (s, 3H); 4.28 (q, 2H, J ¼ 7.34 Hz); 4.70 (s, 2H); 7.22 (t, 1H,
J ¼ 6.30 Hz); 7.35 (t, 1H, J ¼ 6.30 Hz); 7.42 (d, 1H, J ¼ 8.10 Hz); 7.49
(d, 1H, J ¼ 8.10 Hz); 7.53 (s, 1H); 7.55e7.60 (m, 2H); 8.16 (d, 1H,
J ¼ 7.80 Hz); 8.27 (d, 1H, J ¼ 7.80 Hz).
A solution of TBAF 1M in THF (63 mL, 64 mmol) was added to a
solution of 10 (35 mg, 64 mmol) in THF (420 mL) cooled at 0 C. The
mixture was stirred for 10 min at 0 C and quenched with EtOAC
and H2O. Organic layer was washed with a saturated solution of
NaHCO3 and brine, dried over anhydrous Na2SO4 and concentrated
in vacuo affording ﬁnal compound 11 (Yield: 45%). 1H NMR (CDCl3,
300 MHz) d (ppm) ¼ 1.50 (t, 3H, J ¼ 7.34 Hz); 4.15 (s, 3H); 4.26 (q,
2H, J ¼ 7.34 Hz); 4.80 (s, 2H); 7.22 (t, 1H, J ¼ 6.30 Hz); 7.35 (t, 1H,
J¼ 6.30 Hz); 7.42 (d,1H, J¼ 8.10 Hz); 7.49 (d,1H, J¼ 8.10 Hz); 7.53 (s,
1H); 7.55e7.60 (m, 2H); 8.16 (d, 1H, J ¼ 7.80 Hz); 8.27 (d, 1H,
J¼ 7.80 Hz). Anal. Calcd. for C23H20ClNO3S C, 64.86; H, 4.73; Cl, 8.32;
N, 3.29; O, 11.27; S, 7.53. Found C, 64.98; H, 4.82; Cl, 8.29; N, 3.21; O,
11.10; S, 7.44.
4.7. Biological evaluation and assay systems
4.7.1. Animals
Male ICR mice, 8 weeks old (Harlan, Italy), were housed 5 per
cage under controlled illumination (12:12 h light:dark cycle; light
on 06.00 h) and standard environmental conditions (room tem-
perature 22 ± 1 C, humidity 60 ± 10%) for at least 1 week before
experimental use. Mouse chow and tap water were available ad
libitum. The experimental procedures were in accordance with
Italian and European regulations governing the care and treatment
of laboratory animals (Permission no. 41/2007B). Animal care was
in compliance with Ethical Guidelines of the IASP and European
Community (E.C. L358/1 18/12/86) on the use and protection of
animals in experimental research. All efforts were made to mini-
mize animal suffering and to reduce the number of animals used.
4.7.2. Paw oedema
Oedema was induced by carrageenan injection (20 mL/paw, 2%
w/v in saline) into the plantar surface of the right hind paw. All
A. Peduto et al. / European Journal of Medicinal Chemistry 108 (2016) 466e475474derivatives were dissolved in DMSO (0.5% v/v in saline), Zileuton
were dissolved in ethanol-cromophor-saline (1:1:18). The paw
volume was measured using a hydroplethysmometer (Ugo Basile,
Varese, Italy) at 2-4-6 h following carrageenan. Mice (n ¼ 6e8 per
group) were treated with 1 or 6f (1e4 mg/kg, i.p.), 6g and 6l
(1e4 mg/kg, i.p.) 30 min before the inﬂammatory insult. A separate
experimental group received zileuton (20 mg/kg, i.p.) used as a
reference drug before carrageenan.
4.7.3. Determination of 5-LOX product formation in cell-based
assays
PMNL were isolated from human blood of adult healthy vol-
unteers, with consent, obtained from the Institute of Transfusion
Medicine, University Hospital Jena, as described [25]. PMNL
(5  106 in 1 ml PG buffer) were preincubated with the test com-
pounds (15min, 37 C) and 5-LOX product formationwas started by
addition of 1 mM CaCl2 and 2.5 mM A23187. After 10 min at 37 C,
the reaction was stopped with 1 ml of methanol. Cells were placed
on ice, centrifuged at 800  g for 5 min at 4 C and the supernatant
was added to methanol. Formed 5-LOX metabolites were extracted
and analyzed by HPLC as described [26]. 5-LOX product formation
is expressed as ng of 5-LOX products per 106 cells, which includes
LTB4 and its all-trans isomers, 5(S),12(S)-di-hydroxy-6,10-trans-
8,14-cis-eicosatetraenoic acid (5(S),12(S)-DiHETE), and 5(S)-
hydro(pero)xy-6-trans-8,11,14-cis-eicosatetraenoic acid (5-H(p)
ETE). Cysteinyl LTs C4, D4 and E4 were not detected, and oxidation
products of LTB4 were not determined.
4.7.4. Expression and puriﬁcation of human recombinant 5-LO from
E. coli, and determination of 5-LOX activity in cell-free systems
E.coli BL21 was transformed with pT3-5LO plasmid, human re-
combinant 5-LOX protein was expressed at 37 C, puriﬁed as
described [27] and immediately used for 5-LOX activity assays. 5-
LOX (0.5 mg) was diluted with PBS/EDTA and pre-incubated with
test compounds. After 15min at 4 C, samples were pre-warmed for
30 s at 37 C, and 2 mM CaCl2 plus 20 mMAAwere added to start 5-
LO product formation. After 10 min at 37 C formed metabolites
were analyzed by HPLC as described for intact cells above.
4.7.5. Induction of mPGES-1 expression in A549 cells and isolation
of microsomes
Preparation of A549 cells and determination of mPGES-1 ac-
tivity was performed as described previously [20]. In brief,
A549 cells (2 x106 cells in 20 ml medium) were plated in 175 cm2
ﬂasks and incubated for 16 h at 37 C and 5% CO2. Subsequently, the
culture mediumwas replaced by fresh DMEM/high glucose (4.5 g/l)
medium containing FCS (2%, v/v). In order to induce mPGES-1
expression, IL-1b (1 ng/ml) was added, and cells were incubated
for another 72 h. Thereafter, cells were detached with trypsin/
EDTA, washed with PBS, and frozen in liquid nitrogen. Ice-cold
homogenization buffer (0.1 M potassium phosphate buffer pH 7.4,
1 mM phenylmethanesulfonylﬂuoride, 60 mg/ml soybean trypsin
inhibitor, 1 mg/ml leupeptin, 2.5 mM glutathione, and 250 mM su-
crose) was added, and after 15 min, cells were resuspended and
sonicated on ice (3  20 s). The homogenate was subjected to dif-
ferential centrifugation at 10,000 g for 10 min and 174,000 g for
1 h at 4 C. The pellet (microsomal fraction) was resuspended in
1 ml homogenization buffer, and the total protein concentration
was determined by Coomassie protein assay. Microsomal mem-
brane fractions were stored at 80 C for several weeks.
4.7.6. Determination of PGE2 synthase activity in microsomes of
A549 cells
Microsomal membranes were diluted in potassium phosphate
buffer (0.1 M, pH 7.4) containing 2.5 mM glutathione to give a ﬁnalconcentration of 50 mg/ml. Test compounds or vehicle (DMSO at a
ﬁnal concentration of 1%) were added, and after 15 min at 4 C, the
reaction (100 ml total volume) was initiated by addition of PGH2
(20 mM, ﬁnal concentration). After 1 min at 4 C, the reaction was
terminated using stop solution (100 ml; 40 mM FeCl2, 80 mM citric
acid, and 10 mM of 11b-PGE2). PGE2 was separated by solid phase
extraction on reversed phase (RP)-C18 material using acetonitrile
(200 ml) as eluent, and analyzed by RP-HPLC (30% acetonitrile
aq þ 0.007% TFA (v/v), Nova-Pak® C18 column, 5  100 mm, 4 mm
particle size, ﬂow rate 1 ml/min) with UV detection at 195 nm.11b-
PGE2 was used as internal standard to quantify PGE2 product for-
mation by integration of the area under the peaks. IC50 values were
assessed by three determinations at compound concentrations of
0.1, 1, 10 mM.
Appendix A. Supplementary data
Supplementary data related to this article can be found at http://
dx.doi.org/10.1016/j.ejmech.2015.11.048.
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